Cargando…
Brexanolone therapeutics in post-partum depression involves inhibition of systemic inflammatory pathways
BACKGROUND: Brexanolone has rapid, long-lasting, and remarkable efficacy in the treatment of post-partum depression (PPD). We test the hypothesis that brexanolone inhibits proinflammatory modulators and macrophage activation in PPD patients, which may promote clinical recovery. METHODS: PPD patients...
Autores principales: | Balan, Irina, Patterson, Riah, Boero, Giorgia, Krohn, Holly, O'Buckley, Todd K., Meltzer-Brody, Samantha, Morrow, A. Leslie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9984433/ https://www.ncbi.nlm.nih.gov/pubmed/36801618 http://dx.doi.org/10.1016/j.ebiom.2023.104473 |
Ejemplares similares
-
Neurosteroid allopregnanolone (3α,5α-THP) inhibits inflammatory signals induced by activated MyD88-dependent toll-like receptors
por: Balan, Irina, et al.
Publicado: (2021) -
(3α,5α)3-Hydroxypregnan-20-one (3α,5α-THP) Regulation of the HPA Axis in the Context of Different Stressors and Sex
por: Boero, Giorgia, et al.
Publicado: (2022) -
Brexanolone in Postpartum Depression: Post Hoc Analyses to Help Inform Clinical Decision-Making
por: Gerbasi, Margaret E., et al.
Publicado: (2021) -
Open‐label, proof‐of‐concept study of brexanolone in the treatment of severe postpartum depression
por: Kanes, Stephen J., et al.
Publicado: (2017) -
Efficacy of brexanolone in postpartum depression
por: Rodríguez Mercado, C. M.
Publicado: (2023)